Loading stock data…
ONC
$268.17-2.63 (-0.97%)
After Hours$268.17+0.00 (+0.00%)· Last close Jun 9
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BeOne Medicines AG in the Healthcare sector is trading at $268.17 with a market capitalization of $32.1B. Wall Street consensus targets $411.91 (28 analysts), implying a +53.6% move over the next 12 months. The stock is currently near its 52-week low of $239.25, remaining 16.2% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +53.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$268.17
Potential Downside
69%
Whystock Fair Value$83.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus28 analysts
Mean target$411.91+53.6%
Range$333.00 – $501.30
Fundamentals
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$32.06B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
69.92
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.78%
Volume
Today's trading volume
501,834
Recent News
BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?
BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BeOne Medicines (ONC) Valuation Check After ASCO 2026 Solid Tumor Updates
BeOne Medicines (ONC) is back in focus after ASCO 2026 updates on three solid tumor drugs: its CDK4 inhibitor in breast cancer, a B7-H4 antibody drug conjugate in ovarian cancer, and a GPC3x4-1BB bispecific in liver cancer. See our latest analysis for BeOne Medicines. Despite the clinical buzz around ASCO, BeOne Medicines’ recent 30 day share price return is down 5.9% and the year to date share price return is down 10%. However, the 1 year total shareholder return is 8.92% and the 3 year...
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development. John Oyler, BeOne’s co-founder, chairman and chief
How The BeOne Medicines (ONC) Story Is Shifting With Sonrotoclax And Brukinsa
The latest analyst update on BeOne Medicines fine tunes the model fair value estimate from US$408.32 to US$411.51 per share, reflecting incremental shifts in long term assumptions. Recent commentary links this change to how the first FDA accelerated approval for sonrotoclax and the evolving outlook for Brukinsa contribute to differing views on growth durability and execution risk. As you read on, you will see how these moving pieces shape the evolving narrative and what to watch to stay on...
Leerink Raises its Price Target on BeOne Medicines (ONC)
BeOne Medicines AG (NASDAQ:ONC) is one of the 10 Best European Growth Stocks to Buy. On May 15, 2026, Leerink raised the firm’s price target on BeOne Medicines AG (NASDAQ:ONC) to $367 from $364 while maintaining an Outperform rating on the shares. The firm noted that the FDA granted accelerated approval to sonrotoclax for the […]